Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Fleishman

Obstetrics & Gynecology Fort Myers, FL Medical Doctor

NPI 1265414437 CMS profile 11411

9021 Park Royal Dr, Fort Myers, FL 33908

Open in the dashboard

General payments

$64,585

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$5

5 holdings reported · through program year 2025

Research they led as principal investigator

$463,765 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Kevin Fleishman of Fort Myers, FL is reported in the CMS Open Payments database as having received $64,585 across 268 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $463,765 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,032 33
2024 General $6,180 37
2023 General $14,592 36
2022 General $1,791 33
2021 General $29,933 56
2020 General $2,320 22
2019 General $7,738 51
2024 Ownership $1 1
2023 Ownership $1 1
2022 Ownership $1 1
2021 Ownership $1 1
2020 Ownership $1 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Fleishman
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Kevin Fleishman were reported at $2,032. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Kevin Fleishman Obstetrics & Gynecology median Middle half National median
2019 $7,738 $172 $62–$391 $163
2020 $2,320 $94 $36–$222 $114
2021 $29,933 $136 $42–$369 $132
2022 $1,791 $160 $50–$433 $149
2023 $14,592 $169 $56–$423 $160
2024 $6,180 $152 $50–$371 $164
2025 $2,032 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $30,755 27 payments
  2. Astellas Pharma US Inc $12,757 26 payments
  3. AbbVie, Inc. $8,810 44 payments
  4. Organon LLC $7,692 19 payments
  5. Medtronic, Inc. $981 11 payments
  6. Hologic, LLC $485 22 payments
  7. Applied Medical Resources Corporation $428 2 payments
  8. Myovant Sciences Inc. $277 10 payments
  9. Sumitomo Pharma America, Inc. $241 13 payments
  10. Amgen Inc. $218 9 payments
  11. Other $1,940 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $28,221 16 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,565 11 payments
  3. Food and Beverage $7,517 216 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $7,503 9 payments
  5. Travel and Lodging $2,779 16 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $30,755 27 payments
  2. Veozah $12,615 17 payments
  3. NEXPLANON $7,665 17 payments
  4. Orilissa Endocrinology $6,955 24 payments
  5. TruClear $963 10 payments
  6. ORIAHNN $880 7 payments
  7. ORILISSA Womens Health $713 5 payments
  8. MYFEMBREE $416 18 payments
  9. GELPOINT VPATH $377 1 payment
  10. LILETTA $218 11 payments
  11. Other $3,131 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

262

Median for Obstetrics & Gynecology: 65

Drug cost

$25,211

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

38.5%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 18 $11,391
Prometrium Progesterone, Micronized Brand 11 $5,516
Estradiol Generic 72 $2,709
Risedronate Sodium Generic 14 $1,962
Estradiol (Twice Weekly) Estradiol Brand 21 $1,539
Progesterone Progesterone, Micronized Brand 28 $1,024
Acyclovir Generic 16 $257
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $237
Fluconazole Generic 12 $196
Gabapentin Generic 24 $142

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$29,166

Medicare's payments for the services billed

Medicare patients

141

Average age 72

Services billed

401

141 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 52%
Osteoporosis 27%
Depression 26%
Ischemic heart disease 21%
Diabetes 17%
COPD 12%
Chronic kidney disease 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $3,243
$3,243 — —
APONVIE
  • Heron Therapeutics, Inc. $104
$104 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $56
$56 — —
SLYND
  • Exeltis, USA Inc. $56
$56 — —
ABRYSVO
  • PFIZER INC. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record